Introduction
UL) impairments, ®
DISEASE, MULTIPLE SCLEROSIS (MS), DEMYELINATING DISEASE
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the Central Nervous System (CNS) [MS is characterised by a wide range of symptoms and progression patterns, which significantly impact the quality of life of affected individuals. Specifically, upper limb (UL) impairments have a high prevalence, influencing functionality, independence and quality of life [Although clinical and functional impairments in the lower limbs have been extensively studied in patients with MS, the UL are also frequently affected [Despite the emergence of new drugs aimed at modifying the course of the disease, there is currently no curative treatment for MS. Therefore, pharmacological therapy is complemented with rehabilitation treatment to maintain functional capacity and promote adaptation to the changes caused by the progression of MS [One of the devices that can be linked to VR systems is the MYO Armband® surface electromyography (sEMG) and motion capture sensor (Thalmic Labs), which was designed to recognise forearm gestures based on muscle activation. The sensor consists of eight surface electrodes and a 9 degrees of freedom inertial measurement unit (IMU) that includes an accelerometer, magnetometer and gyroscope, each with three degrees of freedom. MYO Armband® has a signal tracking frequency of 200 Hz for sEMG and 50 Hz for the IMU, allowing for three-dimensional motion data collection [The development of these new VR technologies has provided professionals working in the field of neurological rehabilitation with the opportunity to extend patient care for individuals with MS as a complement to their conventional rehabilitation program, achieving higher treatment intensity and sometimes at a sustainable cost [For the reasons described above, conducting a randomised controlled trial (RCT) to study the effects of the MYO Armband® motion capture device, through specifically designed games, as an adjunct to conventional treatment for individuals with MS is justified.